Skip to main
EKSO
EKSO logo

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc. is poised for significant revenue growth, with a projection of $23 million for 2025, primarily driven by increased placement of EksoNR devices following a strong quarterly performance that demonstrated 21%-24% quarter-over-quarter growth. The potential scaling of revenue from the Indego Personal segment, contingent on successful navigation of initial claims and reimbursement strategies, highlights a promising long-term growth outlook. Additionally, the company's strategic partnerships and anticipated demand in key regional markets, particularly Europe, underscore opportunities for expanding its market presence and enhancing overall value.

Bears say

Ekso Bionics Holdings Inc reported total revenue of $17.9 million in 2024, representing a 2% year-over-year decline from the previous year's record revenue of $18.3 million, primarily due to reduced enterprise sales linked to procurement cycle fluctuations in integrated delivery networks. Despite some revenue growth in Europe, especially in France, the overall decline highlights vulnerability in the company's sales performance in its core markets. Additionally, the reported loss on the revaluation of warrant liabilities suggests potential financial instability, contributing to a negative outlook on the company's stock.

EKSO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 5 analysts, EKSO has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.